Log in with your email address username.


[Department of Error] Department of Error

Powles T, Durán I, van der Heijden M, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018; 391: 748–57—In the Results section of this Article, in the sentence that reads “For patients receiving chemotherapy, vinflunine outperformed study expectations; unstratified HRs were 0·95 (95% CI 0·62–1·45) and 0·69 (0·44–1·10) in subgroups based on chemotherapy stratification with vinflunine (n=106) and taxanes (n=128), respectively”, the totals for vinflunine and taxanes are the wrong way around.